Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

(Anti-thymocyte Globulin [Rabbit]) and Lymphoglobuline(R) (Anti-

thymocyte Globulin [Equine]) rose 11 percent to $43.7 million from

$39.4 million. Worldwide demand for Thymoglobulin remains strong. The

product's growth over the past several quarters has been hindered by

supply constraints caused by a manufacturing issue during 2007 that

affected product appearance in some lots. Genzyme instituted a

procedure at its French manufacturing plant at the end of last year

that resolved this manufacturing issue. The company continues to

monitor Thymoglobulin lots produced last year and, if necessary, will

recall any lots that are expected to go out of specification prior to

the originally established expiry period. Genzyme expects

Thymoglobulin sales to accelerate in the second-half of this year as

supply levels increase to meet full demand for the product.

-- Within the Biosurgery business, sales of Synvisc(R) (hylan G-F 20) and

Synvisc-ONE(TM) (hylan G-F 20) rose to $56.1 million from $53.6

million, an increase of 5 percent. Synvisc-One received CE Mark

approval in the European Union in December, and Genzyme is preparing to

introduce the product into the marketplace, where it will be the only

treatment of its kind to provide six months of pain relief with a

single injection. The company has already launched the product in the

United Kingdom, Germany and Italy. Genzyme will pursue marketing

approvals for Synvisc-One in Canada, Asia and Latin America based on

the European CE mark approval, and FDA action on a marketing

application in the United States is expected later this year. By

simplifying osteoarthritis pain management and thereby reaching a

broader set of patients, Synvisc-ONE is expected to drive the

significant growth
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Vycom announces ... of products, designed to meet Factory Mutual (FM) 4910 ... materials such as wet benches, process tools, fume hoods, ... safety and damage to semiconductor wafers used in electronic ... a flame-retardant PVC solution with excellent workability and superior ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014   ... that designs and develops novel diagnostics to personalize and ... the appoint of Gregory T. Lucier as ... previously chairman and CEO of Life Technologies (formerly Invitrogen). ... expertise as Epic commercializes its circulating rare cell analysis ...
(Date:7/30/2014)... CA (PRWEB) July 30, 2014 ... from the U.S. Environmental Protection Agency (EPA). This ... in developmental toxicity models, including tests designed to ... formation and the formation of connections between neurons ... of neurodifferentiation and synapse formation by environmental pollutants ...
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report ... Funding” report provides in-depth analysis of the current ... venture capital segments of the financial industry, bearing ... significant impact on the future of emerging biotechnology ... report identifies regions of the world that are ...
Breaking Biology Technology:Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4
... Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial ... Net loss for the quarter ended September 30, 2009 improved to ... loss of $37.0 million or $0.40 per share in the third ... improvements to its operating efficiencies as compared to a year ago. ...
... /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today ... Department of Health and Human Services (HHS) to present ... November 5, 2009 at 2:40 pm (EST) at the ...
... Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced ... discussing the Company,s 2009 third quarter results on Tuesday, November ... Chairman & Chief Executive Officer, as well as other members ... the Company. A press release reporting the 2009 third quarter ...
Cached Biology Technology:Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10Medicago to present at the U.S. Department of Health and Human Services' Global Health Security Initiative Workshop 2Advanced Life Sciences to Host 2009 Third Quarter Financial Results Conference Call and Webcast 2
(Date:7/30/2014)... studying the potential effects of climate change on ... on the wrong factors, according to a new ... Conservation Society, University of Queensland, and other organizations. ... science is missing the point when it comes ... of climate change scientists focus on the "direct" ...
(Date:7/30/2014)... a joint venture between The University of Texas at ... Science Center at San Antonio, has selected the winners ... Boice from UTSA and Lei Huang from the Health ... "Novel engineered ferritins for tracking and protecting neural stem ... is focused on finding a treatment for stroke through ...
(Date:7/30/2014)... by Clemson University associate professor Andrew S. Mount, performed ... the way for novel anti-fouling paint for ships and ... applications. , The team,s findings, published in ... of barnacles that attaches to a wide variety of ... acts as an underwater heavy-duty adhesive. , "In previous ...
Breaking Biology News(10 mins):Conservation scientists asking wrong questions on climate change impacts on wildlife 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... Clemson University assistant professor of engineering and ... National Science Foundation Faculty Early Career Development (CAREER) ... students, decisions to enter engineering fields. Trenor ... theory of social capital to better understand undergraduate ...
... in Spanish . , Increasing calcium intake is ... a study supported in part by the Agricultural Research Service ... to help the body utilize calcium. The study also may ... with this problem. Currently, calcium intake recommendations are not ...
... a bacterium found in about 50% of humans worldwide, can cause ... for F1000 Medicine Reports , Seiji Shiota and Yoshio Yamaoka ... Infection by the H. pylori bacterium can approach ... but many develop problems including stomach ulcers. H. pylori ...
Cached Biology News:Clemson researcher receives grant to study engineering enrollment of women, minorities 2Vitamin D and calcium interplay explored 2Preventing gastric cancer with antibiotics 2
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
... The 2/3D Waver Shaker combines shaking and rocking ... a 330 x 330 mm stainless steel or ... incubator and cold room operation. The platform angle ... for a vigorous with action and rotation speed ...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
... for 25 chips provides the chips and ... (at picogram levels) with the Experion automated ... HighSens microfluidic chips, 2 x 1,250 microliters ... HighSens stain, 20 microliters RNA ladder, 2 ...
Biology Products: